Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:27:44.457Z.
Calculation as of: 2026-10-06T18:27:44.457Z.
Quote observation: 2026-10-06T18:25:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3dc852dbbee421fd1d0f2104bcbe090e37fdd8a7ae3294fdff0c13dff3b4c360
PE RATIO
N/A
Market Cap
$2.29B
PE Ratio
12.82
TTM Avg
11.87
3Y Avg
13.26
5Y Avg
33.57
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.34B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.34B | 19.20 | 352.62 | 352.62 | 352.62 |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.33B | N/A | N/A | N/A | N/A |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 32.48 | 26.95 | 32.74 | 31.58 |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 14.58 | 17.01 | 39.38 | 39.38 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 12.82 | 11.87 | 13.26 | 33.57 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | N/A | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.24B | N/A | 6.84 | 18.15 | 20.42 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$22.55
Forward EPS (Est.)
$-2.70
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
